Quantcast

Latest Circassia Ltd Stories

2011-06-13 04:00:00

OXFORD, England, June 13, 2011 /PRNewswire/ -- - Results Presented at Plenary Symposium of European Academy of Allergy and Clinical Immunology Congress - Cat Allergy T-cell Vaccine to Begin Phase III Testing in H1 2012 Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune(R) cat allergy vaccine over a 12-week period maintained...

2011-04-19 04:00:00

OXFORD, England, April 19, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million ($98 million) fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual. The investment, which is scheduled in two tranches over the next two years, is the second largest fundraising by a privately-held European...

2011-02-09 03:59:00

OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most...

2011-02-01 03:59:00

OXFORD, England, February 1, 2011 /PRNewswire/ -- - Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile. The successful...

2010-11-18 04:00:00

OXFORD, England, November 18, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a major reduction in patients' reactions to house dust mite allergens. These results build on four earlier successful phase II studies of...

2010-09-30 03:58:00

OXFORD, England, September 30, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.' In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed allergy treatment and progressed phase III development plans for its cat allergy...

2010-02-12 03:00:00

OXFORD, England, February 12 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against...

2010-01-19 05:11:00

OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II. Each of these builds on earlier successful phase II results...

2009-12-11 03:00:00

OXFORD, England, December 11 /PRNewswire/ -- - Investment Follows Successful Phase Ii Clinical Results With cat Allergy T-cell Vaccine - Funding to Progress ToleroMune(R) T-cell Allergy Vaccines Into Late-Stage Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders...

2009-11-20 03:00:00

OXFORD, England, November 20 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development. The clinical trial, which was the first of its kind in the field of cat allergy immunotherapy, showed that Circassia's ToleroMune treatment was...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related